Category - Developments

Developments

FDA clears CytoDyn for Phase 2 combo study in metastatic colorectal cancer

The FDA has cleared CytoDyn’s (OTCQB:CYDY) to conduct a Phase 2 study for combination therapy of leronlimab and regorafenib in patients with metastatic colorectal cancer (mCRC). The Phase 2 study is a single arm study...

September 9, 2019

Developments

Soricimed, Image Analysis Group to validate SOR-C13 imaging markers

Soricimed Biopharma entered into a strategic alliance with Image Analysis Group for the development of Soricimed’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel. Image...

September 6, 2019

Developments

NEJM landmark cardiac study included genetic testing with Spartan Bioscience rapid genotyping system

The New England Journal of Medicine published results from a landmark clinical trial called, “Patient Outcome after Primary PCI” (POPular Genetics), that included genetic testing using the Spartan RX CYP2C19 rapid...

September 5, 2019

Developments

Precipio and U of Penn in joint pathology diagnostics collaboration

Precipio (NASDAQ:PRPO) inked a new joint collaboration with the Department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania to expand cancer patient access to...

September 5, 2019

Developments

Versant Ventures launches medtech sector investment firm

Versant Ventures launched an independent new venture capital and growth equity investment firm dedicated to the medtech sector. Vensana Capital debuted with the closing of its inaugural fund, Vensana Capital I, with...

September 5, 2019

Developments

Aerie Pharma upsizes and prices private sale of $275-million of convertible notes

Aerie Pharmaceuticals (NASDAQ:AERI) priced $275-million principal amount of 1.5% convertible senior notes due 2024. The offering was increased to $275-million from a previously announced size of $250-million. The notes...

September 5, 2019

Developments

Repare Therapeutics raises $82.5-million in Series B financing

Closely-held Repare Therapeutics completed an $82.5-million Series B financing as it prepares to take its lead synthetic lethality therapy into human testing in 2020. Cowen Healthcare Investments led the financing and...

September 4, 2019

Developments

CytoDyn files IND and Phase 2 protocol to treat NASH with leronlimab

CytoDyn (OTCQB:CYDY) filed an IND and a Phase 2 clinical trial protocol with the FDA for the treatment of non-alcoholic steatohepatitis (NASH) with its lead drug candidate, leronlimab. Based on published reports of the...

September 4, 2019

Developments

XORTX highlights new polycystic kidney disease research

XORTX Therapeutics (CSE:XRX; OTCQB:XRTXF) said a new research paper that describes a previously unrecognized form of injury that can occur when uric acid or calcium oxalate crystals form in the kidneys of individuals...

September 4, 2019

Developments

Paratek Pharma’s Phase 3 NUZYRA trial results published in The Lancet Infectious Diseases

The results of Paratek Pharmaceuticals’ (NASDAQ:PRTK) Phase 3 trial of NUZYRA for the treatment of acute bacterial skin and skin structure infections (ABSSSI) have been published in the peer-reviewed journal, The Lancet...

August 30, 2019

Category - Developments

FDA clears CytoDyn for Phase 2 combo study in metastatic colorectal cancer

Soricimed, Image Analysis Group to validate SOR-C13 imaging markers

NEJM landmark cardiac study included genetic testing with Spartan Bioscience rapid genotyping system

Precipio and U of Penn in joint pathology diagnostics collaboration

Versant Ventures launches medtech sector investment firm

Aerie Pharma upsizes and prices private sale of $275-million of convertible notes

Repare Therapeutics raises $82.5-million in Series B financing

CytoDyn files IND and Phase 2 protocol to treat NASH with leronlimab

XORTX highlights new polycystic kidney disease research

Paratek Pharma’s Phase 3 NUZYRA trial results published in The Lancet Infectious Diseases

Follow Us

Subscribe

General

More

Subscribe